http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0113696-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40a92325286ca98dbffa06d2c67ed064 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-42 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 |
| filingDate | 2001-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74c47cf3711470f4cda723a8bcbc06d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa4b15d145ab6f9ab0c47a5e025ed3e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a773dee031cd43d3984f85839ed753b6 |
| publicationDate | 2003-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-0113696-A |
| titleOfInvention | A compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound or salt, and methods for treating a disease or disorder associated with pathogenic agonism, to localize gaba receptors in a tissue sample, to inhibit binding of a benzodiazepine compound to a gabaa receptor to alter the signal transducing activity of the gabaa receptors and to prepare a compound |
| abstract | "COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND OR SALT, AND METHODS FOR TREATING A DISEASE OR DISORDER, IN ORDER TO LOCATE A CUSTOMER OF EARLY RECEPTORS, TO INHIBIT THE CONNECTION OF A BENZODIAZEPIN COMPOUND TO A GABA ~ A ~ RECEIVER, TO ALTER THE SIGNAL TRANSDUCTIVE ACTIVITY OF GABA ~ A ~ RECEIVERS AND TO PREPARE A COMPOUND. " Compounds of formula (I) are disclosed, and their pharmaceutically acceptable salts wherein R, Ar, A, n, R, and R2 are defined herein. These compounds are GABA-A ~ brain receptor agonists, antagonists or inverse agonists or GABA-A ~ brain receptor agonists, antagonists or inverse agonists and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and attack disorders, overdose with benzodiazepine medications and memory enhancement. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed. |
| priorityDate | 2000-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415830121 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134664 |
Total number of triples: 26.